Amifampridine
- Generic Name
- Amifampridine
- Brand Names
- Firdapse, Ruzurgi, Firdapse (previously Zenas), Amifampridine SERB
- Drug Type
- Small Molecule
- Chemical Formula
- C5H7N3
- CAS Number
- 54-96-6
- Unique Ingredient Identifier
- RU4S6E2G0J
- Background
Amifampridine, or 3,4-diaminopyridine (3,4-DAP), is a quaternary ammonium compound that blocks presynaptic potassium channels, and subsequently prolongs the action potential and increases presynaptic calcium concentrations . It was first discovered in Scotland in the 1970s and its clinical effectiveness for neuromuscular disorders, including Lambert–Eaton my...
- Indication
用于治疗6岁及以上的成人和儿童患者的一种罕见病自身免疫疾病兰伯特-伊顿（Lambert Eaton）肌无力综合征（LEMS）。LEMS最常见的表现是肌无力，容易疲劳，可导致行走及爬楼梯困难。
- Associated Conditions
- Lambert Eaton Myasthenic Syndrome (LEMS)
- Associated Therapies
- -
Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-02-21
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 126
- Registration Number
- NCT00190268
- Locations
- 🇫🇷
Tenon Hospital, Paris, France
🇫🇷Pontchaillou Hospital, Rennes, France
🇫🇷Pitié Salpetriere Hospital, Paris, France
Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome
Not Applicable
Completed
- Conditions
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- FDA Office of Orphan Products Development
- Target Recruit Count
- 26
- Registration Number
- NCT00004832
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath